SG10201506658TA - Utility of b-raf dna mutation in diagnosis and treatment of cancer - Google Patents

Utility of b-raf dna mutation in diagnosis and treatment of cancer

Info

Publication number
SG10201506658TA
SG10201506658TA SG10201506658TA SG10201506658TA SG10201506658TA SG 10201506658T A SG10201506658T A SG 10201506658TA SG 10201506658T A SG10201506658T A SG 10201506658TA SG 10201506658T A SG10201506658T A SG 10201506658TA SG 10201506658T A SG10201506658T A SG 10201506658TA
Authority
SG
Singapore
Prior art keywords
diagnosis
cancer
treatment
utility
dna mutation
Prior art date
Application number
SG10201506658TA
Other languages
English (en)
Inventor
Dave S B Hoon
Original Assignee
Wayne John Cancer Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wayne John Cancer Inst filed Critical Wayne John Cancer Inst
Publication of SG10201506658TA publication Critical patent/SG10201506658TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG10201506658TA 2007-02-26 2008-02-26 Utility of b-raf dna mutation in diagnosis and treatment of cancer SG10201506658TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89158907P 2007-02-26 2007-02-26
US89324307P 2007-03-06 2007-03-06

Publications (1)

Publication Number Publication Date
SG10201506658TA true SG10201506658TA (en) 2015-09-29

Family

ID=39721826

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201506658TA SG10201506658TA (en) 2007-02-26 2008-02-26 Utility of b-raf dna mutation in diagnosis and treatment of cancer
SG2012012647A SG178814A1 (en) 2007-02-26 2008-02-26 Utility of b-raf dna mutation in diagnosis and treatment of cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2012012647A SG178814A1 (en) 2007-02-26 2008-02-26 Utility of b-raf dna mutation in diagnosis and treatment of cancer

Country Status (7)

Country Link
US (2) US9556491B2 (de)
EP (1) EP2129791A4 (de)
JP (1) JP2010528585A (de)
AU (2) AU2008221468A1 (de)
CA (1) CA2713303A1 (de)
SG (2) SG10201506658TA (de)
WO (1) WO2008106453A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563879B2 (en) * 2001-09-26 2009-07-21 Intrexon Corporation Leafhopper ecdysone receptor nucleic acids, polypeptides, and uses thereof
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
CN103424541B (zh) 2006-05-18 2018-01-30 分子压型学会股份有限公司 确定针对病状的个性化医疗介入的系统和方法
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
US8583380B2 (en) 2008-09-05 2013-11-12 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options
EP3075864A1 (de) * 2008-10-14 2016-10-05 Caris MPI, Inc. Gen und genexprimierte zielproteine zur darstellung von biomarkermustern und signatursets nach tumortyp
EP3722810A3 (de) * 2009-02-11 2021-01-13 Caris MPI, Inc. Molekulare profilierung von tumoren
CN101487051B (zh) * 2009-02-24 2011-07-20 广州益善生物技术有限公司 Braf基因突变的检测探针、液相芯片及其检测方法
US20110177512A1 (en) * 2010-01-19 2011-07-21 Predictive Biosciences, Inc. Method for assuring amplification of an abnormal nucleic acid in a sample
KR101825117B1 (ko) * 2010-02-01 2018-02-06 주식회사 파나진 Ｐｎａ 기반의 실시간 ｐｃｒ 클램핑을 이용한 ｂｒａｆ 돌연변이 검출 방법 및 키트
KR101312241B1 (ko) 2010-04-27 2013-09-27 사회복지법인 삼성생명공익재단 증폭억제시발체를 이용하는 유전자 돌연변이 검출 방법
AU2011272592A1 (en) * 2010-06-30 2013-02-07 Mitsubishi Chemical Medience Corporation Highly sensitive mutated gene detection method
EP2619329B1 (de) 2010-09-24 2019-05-22 The Board of Trustees of The Leland Stanford Junior University Direkte erfassung, amplifikation und sequenzierung einer ziel-dna unter verwendung immobilisierter primer
CN110016499B (zh) 2011-04-15 2023-11-14 约翰·霍普金斯大学 安全测序系统
US10077474B2 (en) * 2012-05-29 2018-09-18 Abbott Molecular, Inc. Method of designing primers, method of detecting single nucleotide polymorphisms (SNPs), method of distinguishing SNPs, and related primers, detectable oligonucleotides, and kits
WO2013190089A1 (en) * 2012-06-21 2013-12-27 Pangaea Biotech, S.L. Molecular biomarkers for predicting outcome in lung cancer
CN104956225B (zh) 2012-10-29 2018-10-02 约翰·霍普金斯大学 卵巢和子宫内膜癌的帕帕尼科拉乌测试
US10373149B1 (en) 2012-11-12 2019-08-06 Square, Inc. Secure data entry using a card reader with minimal display and input capabilities having a display
CA2902099C (en) * 2013-03-08 2020-06-02 F. Hoffmann-La Roche Ag Egfr mutation blood testing
US20160115556A1 (en) * 2013-10-19 2016-04-28 Trovagene, Inc. Detecting mutations in disease over time
US20150132256A1 (en) * 2013-10-19 2015-05-14 Trovagene, Inc. Detecting and monitoring mutations in histiocytosis
WO2015058175A2 (en) * 2013-10-19 2015-04-23 Trovagene, Inc. Detecting and monitoring mutations in histiocytosis
EP3058099A4 (de) * 2013-10-19 2017-06-28 TrovaGene, Inc. Nachweis von mutationen einer krankheit im laufe der zeit
JP6512828B2 (ja) 2014-01-07 2019-05-15 三星電子株式会社Ｓａｍｓｕｎｇ Ｅｌｅｃｔｒｏｎｉｃｓ Ｃｏ．，Ｌｔｄ． ｃ−Ｍｅｔ阻害剤の効能予測または効能検証のためのバイオマーカー
WO2015187512A1 (en) * 2014-06-01 2015-12-10 Trovagene, Inc. Monitoring treatment of histiocytosis with vemurafenib and dabrafenib
CA2957396C (en) * 2014-08-07 2021-03-09 Evrykleia LIANIDOU Method of determining pik3ca mutational status in a sample
KR20160037666A (ko) 2014-09-29 2016-04-06 삼성전자주식회사 KRAS 또는 BRAF의 변이를 이용한 c-Met 저해제의 효능 예측
JP6837632B2 (ja) * 2015-07-17 2021-03-03 凸版印刷株式会社 体液試料の単位量当たりのセルフリーｄｎａ量を健康状態の評価のための指標とする方法
US11286531B2 (en) 2015-08-11 2022-03-29 The Johns Hopkins University Assaying ovarian cyst fluid

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997014793A1 (en) 1995-10-20 1997-04-24 Trustees Of Boston University Nucleic acid clamps
US20040146879A1 (en) * 1998-08-31 2004-07-29 Bayer Healthcare Llc Novel human genes and gene expression products
US7442507B2 (en) * 2005-01-24 2008-10-28 New York University School Of Medicine Methods for detecting circulating mutant BRAF DNA
ES2446250T3 (es) * 2005-05-02 2014-03-06 University Of Southern California Marcadores de metilación del ADN asociados con el fenotipo metilador de islas CpG (CIMP) en el cáncer colorrectal humano

Also Published As

Publication number Publication date
WO2008106453A3 (en) 2008-11-06
SG178814A1 (en) 2012-03-29
CA2713303A1 (en) 2008-09-04
US20080268449A1 (en) 2008-10-30
JP2010528585A (ja) 2010-08-26
US9556491B2 (en) 2017-01-31
US9567640B2 (en) 2017-02-14
US20120295258A1 (en) 2012-11-22
AU2014204427A1 (en) 2014-07-31
AU2008221468A1 (en) 2008-09-04
EP2129791A2 (de) 2009-12-09
WO2008106453A2 (en) 2008-09-04
EP2129791A4 (de) 2010-07-28

Similar Documents

Publication Publication Date Title
SG10201506658TA (en) Utility of b-raf dna mutation in diagnosis and treatment of cancer
HK1216261A1 (zh) 低溫和/或低 值在細胞培養中的使用
HK1199887A1 (en) Diagnosis and treatment of cancer using anti-gpr49 antibody gpr49
EP2064550A4 (de) Prrg4-assoziierte zusammensetzungen und verfahren zu ihrer verwendung für tumordiagnoseverfahren
IL208518A0 (en) Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
HK1167005A1 (en) K-ras and b-raf mutations and anti-egfr antibody therapy k-ras
EP2356446A4 (de) Therapeutische und diagnostische verfahren im zusammenhang mit krebsstammzellen
IL213410A0 (en) Methods and compositions for diagnostic use in cancer patients
IL205864A (en) Methods for the analysis of reeling melanoma cells in metastatic melanoma patients
PT2614832T (pt) Diagnóstico de pré-eclâmpsia
PT2173337E (pt) Fosfoplatinas e a sua utilização no tratamento de cancros resistentes à cisplantina e carboplatina
EP2271325A4 (de) Verfahren und verfwendung zur einleitung von apoptose bei krebszellen
IL217120A0 (en) Single nucleotide polymorphisms in brca1 and diagnostic methods of assessing cancer risk based on the same
IL205246A0 (en) Methods and compositions for diagnostic use in cancer patients
EP2012798A4 (de) Verwendung von inositol-tripyrophosphat bei der behandlung von tumoren und erkrankungen
EP2086333A4 (de) Isolierte myeloid-ähnliche zellpopulationen und behandlungsverfahren damit
EP2220208A4 (de) Verwendung von haptoglobingenotypisierung zur diagnose und behandlung von herz-kreislauf-erkrankungen
EP2307034A4 (de) Extrakt von coptidis rhizoma und neue verwendung dafür bei der behandlung von atemwegserkrankungen
EP2155785A4 (de) Der nutzen eines hochmolekularen, mit melanomen assoziierten antigens bei der diagnose und behandlung von krebs
EP1973398A4 (de) Verwendung von inosit-tripyrophosphat bei der behandlung von tumoren und krankheiten
PL387312A1 (pl) Zastosowanie sulindaku i/lub jego metabolitu we wspomagającym leczeniu raka jelita grubego u ludzi
EP1907855A4 (de) Genetische und epigenetische änderungen bei der diagnose und behandlung von krebs
GB0818663D0 (en) Gene regulation and its use in therapy
GB0818032D0 (en) Improvements in and relating to analysis of mixed source dna profiles
GB0602106D0 (en) Improvements in and relating to dna matching